WesleyCalhounMD

Clinical Trials

• Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Start of enrollment: 2012 Jul 30

  Completed

  Phase 3

• Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Start of enrollment: 2013 Jul 31

  Completed

  Phase 3

• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Start of enrollment: 2013 Mar 12

  Completed

  Phase 3

• A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Start of enrollment: 2013 Feb 01

  Completed

  Phase 3

• Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Start of enrollment: 2014 Jul 01

  Completed

  Phase 2

• Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Start of enrollment: 2015 Jan 15

  Completed

  Phase 3

• Patiromer With or Without Food for the Treatment of Hyperkalemia Start of enrollment: 2016 Feb 01

  Completed

  Phase 4

• Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Start of enrollment: 2016 Sep 23

  Completed

  Phase 3

• Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents Start of enrollment: 2017 May 02

  Terminated

  Phase 2

• A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. Start of enrollment: 2017 Dec 14

  Completed

  Phase 3

• A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Start of enrollment: 2018 Jan 08

  Completed

  Phase 3

• A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety Start of enrollment: 2018 Jun 18

  Completed

  Phase 3

• Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis to Determine Non-inferiority of the Theranova Dialyzer Compared to the FX80 Dialyzer Start of enrollment: 2018 Sep 14

  Completed

  Not Applicable

• Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Start of enrollment: 2019 Jan 31

  Completed

  Phase 2

• Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Start of enrollment: 2019 Feb 28

  Completed

  Phase 2, Phase 3

• Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004) Start of enrollment: 2019 Apr 29

  Completed

  Phase 1

• HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis Start of enrollment: 2019 Apr 29

  Active, not recruiting

  Phase 1

• A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Start of enrollment: 2019 Jun 15

  Completed

  Phase 4

• CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Start of enrollment: 2019 May 06

  Completed

  Phase 3

• Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants Start of enrollment: 2020 Jul 22

  Completed

  Phase 3

• Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug Start of enrollment: 2020 Sep 04

  Completed

  Phase 2

• Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Start of enrollment: 2020 Nov 20

  Completed

  Phase 4

• Join now to see all